PMX-53 is a Mas-related gene 2 (MrgX2) agonist and C5aR(CD88) antagonist. PMX-53 reduces atherosclerotic lesions in a mouse model of atherosclerosis, inhibits lung metastasis in a mouse breast cancer model, inhibits C5a-induced hypernociception in rats.
Compound PA, also known as Pomalidomide-CO-C5-azide, serves as a ligand for E3 ligase and features a bioorthogonal azide group. This compound is utilized in the synthesis of PROTACs that exhibit anticancer properties [1].
Functionalized von-Hippel-Lindau protein ligand (VHL) for PROTAC research and development; incorporates an E3 ligase ligand plus an alkyl linker with terminal amine ready for conjugation to a target protein ligand. Part of a range of functionalized tool molecules for PROTAC R&D. This product has been recently renamed. The previous name for this product was VH 032 - linker 13 PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license.
Thalidomide-O-C5-acid is a chemically synthesized conjugate that acts as an E3 ligase ligand-linker and combines the cereblon ligand derived from Thalidomide with a linker commonly utilized in PROTAC technology.
Lenalidomide-C5-acid, a Lenalidomide-based E3 ligase ligand-linker conjugate, is utilized for the recruitment of CRBN protein and can be used to synthesize PROTACs [1].
Pomalidomide-C2-amide-C5-azidea, a derivative of pomalidomide, can be used to synthesize an efficient PROTAC molecule targeting CDK9 and enhances antiproliferative activity [1].
(S,R,S)-AHPC-amido-C5-acid is a chemical compound that contains a VHL ligand for the E3 ubiquitin ligase and a PROTAC linker. It can be utilized in the design of XY028-133[1].